The present disclosure relates to compositions for use in the isothermal amplification of nucleic acids in a sample. In particular, the present disclosure provides compositions that include one or more monosaccharides and/or one or more disaccharides and methods for amplifying at least one target nucleic acid in a sample using the disclosed compositions. The present disclosure further provides systems and kits for performing such methods and using such compositions.
Provided herein are improved assays, methods, and systems for determining the amount, concentration, or level of cardiac myosin binding protein C ("cMyC") in a biological sample obtained from a subject. The improved assays, methods, and systems can generate a result (e.g., the amount or level of cMyC) in less than about 1 hour and are highly specific and sensitive.
Aspects of the present disclosure provide an analysis cartridge that allows analyzing cellular components of a fluid sample, such as a blood sample. In certain embodiments, the analysis cartridge comprises a complete blood count (CBC) module for analyzing cells. The CBC module comprises an imaging chamber comprising a top panel and a bottom panel separated by a suitable distance to produce a monolayer of cells between the panels. The CBC module also comprises a mechanism to deliver into the imaging chamber a small volume of fluid, for example, between 0.1 to 2 µl of fluid. Also provided are methods of analyzing fluid samples in the analysis cartridges provided herein.
A method for improving bone formation in an individual comprises administering a bovine milk exosome-enriched product and vitamin K2 to the individual. A method for reducing a risk of bone fracture or strengthening bone in an individual comprises administering a bovine milk exosome-enriched product and vitamin K2 to the individual. A method for preventing or delaying onset or development of osteoporosis in an individual comprises administering a bovine milk exosome-enriched product and vitamin K2 to the individual.
Inductive heating systems and method of controlling the same to reduce biological carryover are disclosed herein. An example system includes an induction heater including a tank circuit, the tank circuit including a work coil and a sense coil. The sense coil is to detect a magnetic field generated by the work coil and to output signals in response to the detection. The example system includes a controller to cause the tank circuit to oscillate at a resonant frequency in response to the signals and a power drive unit in communication with the controller and the induction heater. The power drive unit is to adjust power provided to the induction heater in response to the controller driving the tank circuit to oscillate at the resonant frequency.
A method of promoting healthy catch-up growth in a pediatric individual comprises administering a nutritional composition with an exosome-enriched product comprising intact bovine milk-derived exosomes to the pediatric individual during a period of weight gain. A method also provides promoting healthy catch-up growth in an underweight individual by administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the individual.
Sulfophenyl and polyethylene glycol derivatives of the thyroid hormones L-thyroxine (T4) and triiodothyronine (T3), and methods of making same, are disclosed. Advantageously, the thyroid hormone derivatives are water soluble, have long-term stability, and don't stick to the surface of common container materials. The derivatives were prepared as calibrators, in non-serum-based solutions, for in vitro thyroid immunoassays to measure the concentration of test samples and were found to perform as well as thyroxine/serum-based solutions.
Disclosed are methods of reducing the incidence of necrotizing enterocolitis in an infant, toddler, or child using nutritional compositions including human milk oligosaccharides. The nutritional compositions including the human milk oligosaccharides are effective in reducing inflammation and the incidence of inflammatory diseases.
Light interrogation systems are provided. Systems of interest include a first pinhole plate comprising one or more pinholes each configured for optical alignment with a detection chamber of a plurality of detection chambers, a light source configured to irradiate each detection chamber in the plurality through a pinhole of the first pinhole plate that is optically aligned with the detection chamber, a second pinhole plate comprising one or more pinholes each optically aligned with a pinhole of the first pinhole plate and configured for optical alignment with a detection chamber of the plurality, and an optical sensor configured to collect light from each detection chamber of the plurality through a pinhole of the second pinhole plate that is optically aligned with the detection chamber. Methods of analyzing a sample fluid using a light interrogation system of the invention are also provided.
The invention provides methods for determining or monitoring liver disease status. In particular, systems and methods are provided that employ a subjects age, sex, platelet count and concentrations of Golgi protein 73 (GP73) and laminin gamma-2 monomer (LG2m) to generate a liver disease score which is used to provide a liver disease status (e.g., absence of disease, presence, or stage of the disease).
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
14.
SAMPLE FLUID ANALYSIS DEVICES, CARTRIDGES FOR USE THEREIN, AND METHODS OF USE THEREOF
Sample fluid analysis devices are provided. Devices of interest include a housing configured to receive a cartridge, a manifold, and an interrogation system configured to analyze the sample fluid. Cartridges for use in the subject devices are also provided. Cartridges of interest include a plurality of detection chambers and a fluidic control subsystem for supplying a sample fluid to the plurality of detection chambers including a sample inlet configured to receive the sample fluid, a sample fluid metering chamber for supplying a predetermined volume of the sample fluid from the sample inlet, a mixing chamber for homogenizing the sample fluid with a diluent fluid, and a microfluidic passage fluidic fluidically connecting the sample fluid metering chamber and the mixing chamber. Methods of using the sample fluid analysis devices and cartridges to analyze a fluidic sample are also provided.
Disclosed are nutritional compositions including human milk oligosaccharides that can be administered to preterm infants, term infants, toddlers, and children for improving airway defense mechanisms.
29 - Meat, dairy products, prepared or preserved foods
Goods & Services
Milk; milk products excluding ice cream, ice milk and frozen yogurt; ready to drink dairy based protein food beverages; dairy-based powders for making dairy-based food beverages and shakes
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
On-line health and medical services, namely, providing an interactive database for exchange of information between a medical device user and healthcare providers, delivered via a global computer network.
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
Diagnostic test kit consisting primarily of in vitro diagnostic reagents; diagnostic kits composed of DNA probes, reagents and antibodies for scientific research; diagnostic test devices and kits comprised of reagents for scientific or research use in detecting the presence of microorganisms, infectious agents, antibodies, antigens, and receptors; pharmacological testing kits consisting primarily of immunoassay reagents for the detection of elevated levels of illicit drugs present in bodily fluids of human subjects for forensic use; control and calibrating reagents for medical diagnostic instruments; control and calibrating reagents for laboratory instruments used for in vitro diagnostic testing and analysis; diagnostic reagents for scientific or medical research use; diagnostic test kits consisting primarily of monoclonal antibodies, antigens, buffers, assay components and reagents for scientific or medical laboratory use; control preparations for in vitro diagnostic testing, screening, confirmation and analysis, namely, diagnostic preparations for scientific or research use; diagnostic reagents and chemical reagents for laboratory or research purposes; chemical reagents, namely, solutions used in diagnostic test kits for laboratory or research purposes; diagnostic test kits comprised of reagents for use in diagnostic tests for laboratory or research use; diagnostic preparations for laboratory or research use; diagnostic test kits comprising reagents and assays for laboratory or research use; diagnostic reagents and chemical reagents, not for medical purposes; immunodiagnostic reagents, not for medical purposes; buffer solutions, not for medical purposes; immunoassay test strips, not for medical purposes; kits comprising reagents and assays for testing for the presence of analytes in biological fluids, other fluids and other matrices, not for medical purposes; kits comprising reagents and assays for collecting and testing oral fluid for the presence of drugs and dr
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Dietetic food and substances adapted for medical use; dietary supplements for humans; nutritive preparations and supplements, namely, nutritionally fortified beverages and powders for human consumption for medical purposes; dietetic foods adapted for medical use, namely, liquid nutritive preparations for tube feeding; nutritional and dietary supplements, namely, electrolyte solutions; milk-based infant formula; pediatric nutritive supplements for human use; liquid nutritive supplements for human use; nutritionally fortified beverages and powders for meal replacement for medical purposes; nutritionally fortified supplements in the form of powder beverages; nutritional and dietary supplements, namely, electrolyte replacement solutions; biological replacement tissue valves for the human heart; vascular access grafts; atherectomy lubricant; medical adhesive radiopaque tape; medical diagnostic reagents; diagnostic preparations for medical purposes; drug and alcohol test kits for use in testing bodily fluids, composed primarily of reagents, antigens, storage receptacles, and printed instructions for use therewith, for home and professional uses; drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; drug testing unit, namely, a urine specimen cup containing medical diagnostic test strips; drug tests for home use for the detection of illegal drugs of abuse and commonly abused prescription drugs; home diagnostic testing kits for detecting cholesterol levels in blood, primarily comprised of finger stick devices for drawing blood and test devices containing test strips that react to the presence of cholesterol in blood; diagnostic reagents and chemical reagents, for medical purposes; medical diagnostic and immunodiagnostic reagents, for medical purposes; drug and alcohol testing kits comprising diagnostic and chemical reagents and assays, for medical purposes; drug and alcohol testing kits comprised of diagnostic reagents and assays for
09 - Scientific and electric apparatus and instruments
Goods & Services
Downloadable software for sharing, reporting, maintaining, managing, monitoring, and analyzing medical data; downloadable mobile applications for sharing, reporting, maintaining, managing, monitoring, and analyzing medical data; downloadable software for sharing, reporting, maintaining, managing, monitoring, tracking, analyzing, logging, and measuring analyte data, health-related data, fitness-related data, and nutrition-related data in the fields of health, wellness, disease management, and medical diagnostics; downloadable mobile applications for sharing, reporting, maintaining, managing, monitoring, tracking, analyzing, logging, and measuring analyte data, health-related data, fitness-related data, and nutrition-related data in the fields of health, wellness, disease management, and medical diagnostics; downloadable software and downloadable mobile applications for tracking, managing, and documenting health conditions and medical therapies, including chronic pain, psychiatric disorders, and movement disorders; downloadable medical software for sharing, reporting, maintaining, managing, monitoring, tracking, analyzing, logging, and measuring analyte data, health-related data, fitness-related data, and nutrition-related data; downloadable medical mobile applications for sharing, reporting, maintaining, managing, monitoring, tracking, analyzing, logging, and measuring analyte data, health-related data, fitness-related data, and nutrition-related data; downloadable software for use by patients, their families, and health care professionals enabling users to track and share therapy progress and healthcare information in the areas of chronic pain and movement disorders management; downloadable software for communication and collaboration among medical facilities, clinicians, caregivers, and patients; cloud-based software for storing, analyzing, and managing patient health data; downloadable software for programming, monitoring, and controlling implantable pulse generators and neuromodulation devices; downloadable electronic newsletters and virtual education resources in the field of healthcare; electronic controllers for implanted cardiac assist devices; embedded medical software for recording and analyzing data from patient-worn monitors; display monitors for presenting medical data; computer hardware and software for use in electrophysiology, including collection, mapping, visualization, and analysis of electroanatomical data; interface modules for medical data integration; remote support software for medical systems; medical imaging software and hardware, including optical coherence tomography software and controllers for use with imaging apparatus; tools for receiving, processing, transmitting, and displaying patient medical information; software for linking electrophysiology sensor data with diagnostic images and visualizing intracardiac catheter navigation; scientific instruments, namely sensors, electrodes, signal processors, digitizers, frequency converters, CPUs, and fiber optic force sensors, integrated with software for controlling peripherals and analyzing catheter-based ultrasound imaging data; batteries, battery chargers, power cables, USB chargers, adapter cables, antennas, and portable disc drives for use with medical devices; laboratory instruments for the detection of diseases, namely, camera-based instruments for reading and interpreting lateral flow assays, molecular diagnostics analyzers, automated cell counters, test tubes, tube caps, pipettes, hand-operated laboratory presses, laboratory racks for sample storage vessels, and immunoassay diagnostic slides; laboratory instruments used in research, namely, molecular diagnostic systems for testing patients for respiratory, community acquired, hospital acquired, sexual health, gastro-enteric, vector borne, blood borne pathogen, and tropical disease infections; recorded operating software for medical diagnostic analyzers; recorded software for transmitting data between medical diagnostic analyzers and laboratory information systems; non-medical drug detection devices, namely devices built into a specimen cup to detect the presence of certain drugs relating to substance abuse; laboratory apparatus and instruments for laboratory automation purposes, namely, loading and unloading sample racks, detecting tube characteristics, loading non-rack based laboratory samples, detecting sample tubes, weighing sample tubes, removing caps from sample tubes, centrifuging, transferring samples to new tubes, labeling sample tubes, storing samples, recapping sample tubes, archiving samples, retrieving samples, and disposing of samples; Laboratory apparatus and instruments, namely, input/output modules, tube assessment modules, bulk loader modules, tube assessment centers, centrifuge modules, decapper modules, modules for creating secondary tubes traceable to the primary sample, buffer modules, recapper modules, screw cap modules, archive modules, and remover modules; Automated laboratory equipment mainly for laboratory automation purposes, namely, loading and unloading sample racks, detecting tube characteristics, loading non-rack based laboratory samples, detecting sample tubes, weighing sample tubes, removing caps from sample tubes, centrifuging, transferring samples to new tubes, labeling sample tubes, storing samples, recapping sample tubes, archiving samples, retrieving samples, and disposing of samples; Laboratory robots; computer systems, comprised of software, hardware and interfaces for providing remote monitoring of medical diagnostic equipment, remote automated control and data management capabilities between a central laboratory and remote clinical laboratory instrumentation; data management and laboratory automation system comprised of computer hardware and software for use in the field of medical diagnostics; laboratory equipment for use in the field of medical diagnostics, namely, a unit comprising an input/output module for sorting tubes, centrifuge, decapper, aliquotter, transport or track systems used for the transportation of specimen vials and tubes, resealer/recapper, tube storage unit, and desealer; electronic data interfacing for medical diagnostic instruments; electronic data interfacing for hematology analyzers, clinical chemistry analyzers, immunoassay analyzers, blood screening instruments, and blood, bodily fluid and tissue testing systems; electronic publications, namely, instruction sheets and manuals for in vitro diagnostic instruments, laboratory automation systems recorded on computer media, and related software; research and commercial laboratory analyzers for measuring, testing and analyzing blood, bodily fluids and tissue; laboratory instruments for in vitro diagnostic testing and analysis; laboratory equipment for use in the field of medical diagnostics, namely, laboratory test and collection kits used in connection with in vitro diagnostics; molecular diagnostic systems for the detection, quantitation, identification and functional analysis of nucleic acids, genetic materials, infectious agents and pathogens consisting of sequencers, spectrometers, sensors and computers; automated clinical molecular instruments in the nature of sequencers, spectrometers, sensors and computers; laboratory instruments for microbial screening and identification; laboratory apparatus for genotyping, gene expression analysis, molecular imaging, and DNA sequence analysis; molecular diagnostic systems comprised of sequencers, spectrometers, sensors and computers, for analysis of nucleic acid sequences, nucleic acids, genetic materials, infectious agents or pathogens; automated clinical molecular laboratory instruments, namely, homogenizers; laboratory sample extraction instruments; laboratory apparatus, namely, molecular diagnostic sensors for analysis of nucleic acid sequences, nucleic acids, genetic materials, infectious agents and pathogens; calibration devices for calibrating blood analyzers, hematology analyzers, and analyzers for measuring, testing and analyzing body fluids; laboratory instruments for parasitic screening and identification; cartridges, chambers and chamber trays for use in research and commercial laboratory blood analyzers, research and commercial laboratory hematology analyzers, and research and commercial laboratory analyzers for measuring, testing and analyzing body fluids; integrated workplace drug testing unit, consisting of a digital camera reader, networked point of service monitor, proprietary software, printer, modem and bar code reader; downloadable software in the nature of a mobile application for reporting drug tests and occupational health screening results to employers; downloadable software and mobile applications for use in connection with infectious disease testing; downloadable software and mobile applications for infectious disease data and information management; downloadable software and mobile applications for use in the field of infectious disease testing; downloadable software and mobile applications for receiving, storing, displaying, tracking, sharing, reporting, maintaining, and managing infectious disease data and information; downloadable software for administering, scanning, interpreting, and reporting and information in the fields of toxicology, forensics, drug testing, and alcohol testing; downloadable mobile applications for administering, scanning, interpreting, and reporting data and information in the fields of toxicology, forensics, drug testing, and alcohol testing; downloadable software and downloadable mobile applications for administering, scanning, and interpreting results of rapid drug screening devices; downloadable software and downloadable mobile applications for administering, scanning, and interpreting results of rapid alcohol screening devices; drug testing cups for laboratory use for the detection of drugs in blood or other bodily fluids, not for medical purposes; alcohol testing cups for laboratory use for the detection of alcohol in blood or other bodily fluids, not for medical purposes; laboratory devices for analyzing blood and other bodily fluids, for drug and alcohol screening and testing, not for medical purposes; laboratory devices for rapid drug screening testing, not for medical purposes, for the simultaneous, qualitative detection of multiple drugs and metabolites in human urine; forensic drug and alcohol testing kits comprising non-medical laboratory devices for analyzing blood and other bodily fluids, not for medical purposes; forensic kits comprising non-medical laboratory devices for testing for the presence of analytes in biological fluids, other fluids and other matrices, not for medical purposes; kits comprising non-medical laboratory devices for collecting and testing biological fluid for the presence of drugs and drug metabolites, not for medical purposes; kits comprising non-medical laboratory devices for collecting and testing biological fluid for the presence of alcohol and metabolites, not for medical purposes; downloadable webinars in the field of healthcare; downloadable computer software and hardware for hematology analyzers, clinical chemistry analyzers, immunoassay analyzers, blood screening instruments, and instruments for blood, bodily fluid and tissue testing; computer hardware and downloadable software for use in the field of medical diagnostics; downloadable software and hardware for medical diagnostic instruments
Medical diagnostic instruments for diabetes diagnosis and monitoring; medical diagnostic instruments for analyzing, measuring and testing blood, bodily fluids and tissue; medical diagnostic instruments for in vitro diagnostic testing and analysis, namely, sample handlers, sample preparation equipment, equipment for testing bodily fluids for medical diagnosis; medical diagnostic instruments for microbial screening and identification, analysis of nucleic acid sequences, nucleic acids, genetic materials, infectious agents and pathogens; medical and surgical apparatus and instruments, namely, stents, catheters, guide wires, bioabsorbable stents, drug-eluting stents, scaffolding for catheters and stents for use in vascular procedures; medical apparatus and equipment, namely, patient monitor that is for use in electronic acquisition, capture and transmission of medical device status and patient medical and physiological data used in connection with implantable cardiac devices, and external or implantable cardiac therapeutic or diagnostic devices; medical diagnostic instruments for testing patients for respiratory, community acquired, hospital acquired, sexual health, gastro-enteric, vector borne, blood borne pathogen, and tropical disease infections; medical diagnostic apparatus and incorporated recorded computer software for analyzing medical data and informing treatment decisions, all sold as a unit, for medical diagnostic use; medical apparatus and instruments, namely, blood glucose meters, blood ketone meters, biosensors and biosensor applicators for measuring blood glucose, blood ketone, and blood lactate levels, electrochemical sensors for measuring analyte concentrations in interstitial fluid, electrochemical sensors for monitoring analyte levels in interstitial fluid, electrochemical sensors for monitoring analyte concentrations in bodily fluids, electrochemical sensors for monitoring analyte levels in bodily fluids, electrochemical sensors for monitoring analytes in bodily fluids, needles for injecting insulin, medical infusion pumps for delivering measured amounts of solutions into the bloodstream over time, and insulin pumps; blood, bodily fluid, tissue, and fecal matter medical testing instruments; medical apparatus for monitoring, tracking, and determining analyte concentrations; sensors for monitoring, tracking, and determining analyte concentrations for health purposes; medical apparatus and instruments for monitoring glucose; medical apparatus and instruments for monitoring ketones; instruments and apparatus for monitoring glucose for health purposes; instruments and apparatus for monitoring ketones for health purposes; patient monitoring sensors for monitoring glucose concentrations; patient monitoring sensors for monitoring ketone concentrations; sensor-based glucose monitors for medical purposes; sensor-based ketone monitors for medical purposes; medical devices, namely, catheters and catheter interface modules; medical and surgical catheters; enteral nutritional delivery system, namely, feeding tubes; breastmilk storage bottle; infant formula storage bottle, sold empty; baby bottles; baby nursers; medical and surgical apparatus and instruments, namely, implantable cardiac devices including pacemakers, implantable cardioverter defibrillators (ICDs), and pulse generators; stimulation leads; implantable heart monitors; neurostimulators; telemetry systems for device communication; electrophysiology systems comprising sensors, amplifiers, stimulators, and software; catheter-based technologies including balloon dilatation catheters, ablation catheters, mapping catheters, steerable catheters, introducer kits, guide wires, and delivery systems; vascular tools including drug-eluting and self-expandable stents, occlusion and filtration devices, thrombectomy systems, and embolic protection devices; orbital atherectomy systems; heart assist devices including ventricular assist devices, catheter pumps, percutaneous heart pumps, blood pumps, and cannula kits; prosthetic heart valves, annuloplasty rings, cuffs, and bioprosthetic repair products; surgical tools including coring knives, slitting tools, sewing rings, anastomotic devices, sizers, tunnelers, hand pumping bulbs, and stabilization belts; arterial closure devices; oxygenators; perfusion tubing; braided intravascular sheaths; bleed back control valves; diagnostic sensors; delivery catheters; wearable external components for heart assist devices including batteries, display monitors, microprocessors, and chargers; imaging and navigation systems using ultrasound, optical coherence tomography, and 2D/3D localization; software modules for implanted device monitoring and diagnostics; diagnostic apparatus for the medical analysis of bodily fluids and tissue; cartridges for use in portable clinical blood analyzers; specimen collection kit, consisting of diagnostic instruments for the analysis of bodily fluids and tissue; microbial tubes for blood testing; blood testing apparatus; electronic simulators and cartridges for use in portable clinical blood analyzers; diagnostic apparatus for medical purposes, namely, for diagnosing pregnancy, fertility, and infectious diseases; medical diagnostic apparatus and instruments for detecting the presence and measuring the level of drugs and alcohol in blood and other body fluids; Medical apparatus and instruments for the screening of drugs and alcohol, namely, medical diagnostic devices for analyzing blood and other bodily fluids for the presence of drugs and alcohol; medical instruments, namely self-processing diagnostic instrument for processing of test cartridges containing chemical reagents for in-vitro diagnostic medical testing; with a detection principle based on digital camera technology; medical devices, namely, camera-based instruments for reading and interpreting lateral flow assays for medical diagnostic and treatment purposes; medical devices, namely, camera-based instruments for reading and interpreting in vitro diagnostic tests for influenza, strep, pneumonia, and legionella; medical diagnostic instruments and parts therefore for molecular diagnostic analysis; medical diagnostic analyzers and parts therefore for detecting and managing infectious diseases; medical apparatus for determining and analyzing in vitro molecular interactions; medical apparatus for analyzing molecules, cells, tissues and organisms for detecting and managing infectious diseases; medical apparatus for analyzing nucleic acid and proteins for diagnosis and testing of infectious diseases; medical instruments used for blood, bodily fluid and tissue testing; nucleic acid medical testing instruments for diagnosis and management of infectious diseases; medical diagnostic instruments for detection of infectious diseases; pre-filled cartridges for detecting and managing infectious diseases; hematology analyzers for medical diagnostic use; clinical chemistry analyzers for medical diagnostic use in testing bodily fluids; immunoassay analyzers for medical diagnostic use; blood screening instruments for medical use; medical diagnostic instruments for in vitro diagnostic testing and analysis; molecular diagnostic instruments for the analysis of body fluids; medical diagnostic instruments, namely, sample handlers, sample preparation equipment, equipment for testing bodily fluids for medical diagnosis; specimen collection kits used in connection with in vitro diagnostics; blood analyzing instruments and systems for medical diagnostic purposes; medical diagnostic analyzers for measuring, testing and analyzing body fluids; cartridges, chambers and chamber trays for medical use in medical diagnostic blood analyzers, medical diagnostic hematology analyzers, and medical diagnostic analyzers for measuring, testing and analyzing body fluids
Fruit-based beverages; vegetable juices and smoothies; fruit juices and smoothies; powders used in the preparation of fruit-based beverages and vegetable-based beverages; non-alcoholic fruit-flavored beverages; drinking water containing electrolytes; sports drinks containing electrolytes; sport drinks, namely, performance drinks.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Providing temporary use of on-line non-downloadable software for sharing, reporting, maintaining, managing, monitoring and analyzing of medical information in the field of diabetes management; Providing a website featuring on-line non-downloadable software that enables users to share, report, maintain, manage, monitor and analyze medical information in the field of diabetes management; Software as a service (SAAS) services featuring software for sharing, reporting, maintaining, managing, monitoring and analyzing of medical information in the field of diabetes management; providing temporary use of non-downloadable web-based software and software as a service (SaaS) for remote patient medical monitoring, including software for collecting, transmitting, analyzing, and managing health data, testing results, and medical device functionality; providing web-based portals for patients and medical providers to access healthcare information; cloud-based platforms for managing and documenting medical therapies and disease states; software for medical provider and patient communication; software for electronically managing and processing patient health data; providing technical support services, namely, troubleshooting, remote software updates, and real-time support for medical devices and electrophysiology equipment; providing technical support via telephone for patients with implanted medical devices; providing online non-downloadable software for medical diagnosis, including measurement and assessment of physiological variables and intravascular imaging; clinical research and providing information about results of medical and scientific research in the field of transcatheter medical devices; consulting regarding medical diagnostic software; consulting regarding medical software; consulting regarding software in the field of health; installation, maintenance and repair of software related to medical diagnostic instruments; providing technical support, namely, troubleshooting regarding laboratory software in the field of medical diagnostics; consulting services in the field of laboratory testing; consulting services in the field of medical diagnostics; consulting regarding the quality control of laboratory instruments for the purpose of gathering operational data and testing data; consulting regarding the quality control of medical diagnostic instruments for the purpose of gathering operational data and testing data; installation, maintenance and repair of software and hardware related to medical diagnostic instruments; remote electronic operational monitoring of diagnostic laboratory systems, laboratory automation systems, and medical diagnostic instruments; providing platform as a service (PAAS) featuring a web-based software platform for laboratory and medical diagnostic information management; software as a service (SAAS) services featuring software for laboratory and diagnostic equipment information management, monitoring and analysis in the field of medical diagnostics; software as a service (SAAS) featuring software for laboratory and diagnostic equipment information management, monitoring and analysis services in the field of health; platform as a service (PAAS) in the field of health, featuring software platforms for laboratory and diagnostic equipment information management, monitoring and analysis in the field of in vitro diagnostics; conducting medical diagnostic testing facility evaluations to assess, quality, environmental sustainability, waste, efficiency, operational downtime, flexibility and agility, namely, quality management evaluations of the medical diagnostic facilities of others to assess steps required to attain optimal efficiency; conducting operational research, monitoring and analysis regarding medical diagnostic instruments, tests and assays, namely, evaluations of the quality and performance of medical diagnostic instruments, tests and assays; analyzing and reporting operational research data, namely, compiling, analyzing and reporting information regarding the performance of medical diagnostic instruments, tests and assays; monitoring, analyzing and reporting services, namely, quality control in the field of medical laboratory equipment operations, medical laboratory inventory management, medical laboratory quality management; data and information management, tracking, analyzing and reporting in the field of medical diagnostics, namely, tracking, analyzing and reporting of performance data for medical diagnostic equipment using computers and sensors; software as a service (SAAS) services featuring software for managing, integrating and facilitating access to medical and patient care data, software for point of care data management, and software for providing interfaces between medical diagnostic devices and laboratory information systems; software as a service (SAAS) featuring software for scientific purposes for toxicology reporting in the fields of forensics and drug testing; software as a service (SAAS) featuring software for scientific purposes for facilitating testing and analysis in the fields of forensics and drug testing; hosting a website featuring online databases for the provision of information in the fields of toxicology, forensics, and drug testing; providing updates for software; laboratory toxicology services; laboratory drug testing services; design and development of computer software for use with medical and non-medical technology; providing technical support services, namely, troubleshooting in the nature of diagnosing problems with medical equipment and related computer hardware and software, monitoring for the purpose of determining the need for repair for medical diagnostic instruments and related computer software and hardware; providing operational monitoring services for medical diagnostic instruments to ensure proper functioning; remote monitoring of medical diagnostic systems to ensure proper functioning; providing remote electronic monitoring and troubleshooting of medical diagnostic instruments to ensure proper functioning; providing a web-based non-downloadable software platform for data management, monitoring and analysis in the field of medical diagnostics; computer services, namely, providing a web-based non-downloadable software platform for data management, tracking, reporting, sharing, monitoring and analysis for medical diagnostic instruments; computer services, namely, providing a web-based non-downloadable software platform for data management, tracking, reporting, sharing, monitoring and analysis for medical diagnostic systems; computer services, namely, monitoring and reporting on the performance and errors of medical diagnostic instruments; providing an on-line network environment that features technology that enables users to share data in the field of medical diagnostics; providing temporary use of non-downloadable software and applications for monitoring medical diagnostic instruments and managing data from medical diagnostic instruments; providing a website featuring technology that enables users to manage drug and alcohol testing data, order, schedule and pay for drug and alcohol screening testing services. Providing a website that enables users to obtain test results of drug and alcohol screening tests. Online computer software as a service featuring software for hiring program management, automated random drug testing, and electronic physical examinations. Providing temporary use of a web-based software application for transmitting, storing and reporting medical exam results, duplicating data and digital information, creating and managing digital images of standardized employment medical forms, online scheduling of medical appointments, downloading and completing medical and health forms and online tracking of medical exams results; platform as a service (PAAS) featuring a web-based software platform in the field of health, for monitoring laboratory operations; platform as a service (PAAS) featuring a web-based software platform in the field of medical diagnostics, for analyzing bodily fluid and tissue samples; conducting laboratory, healthcare facility and healthcare system operational research
25.
DROPLET ACTUATOR FABRICATION APPARATUS, SYSTEMS, AND RELATED METHODS
Example methods, apparatus, systems for droplet actuator fabrication are disclosed. An example non-transitory computer readable medium includes instructions that, when executed, cause at least one processor to at least control movement of a laser to cause the laser to etch an electrode pattern in a first substrate, the electrode pattern including a first set of electrodes, a second set of electrodes, and a third set of electrodes; control a printer driver to cause a hydrophobic material and a dielectric material to be applied to the second set of electrodes and not the first set of electrodes via a printer; control a bonding driver to cause a gap to be defined between the first substrate and a second substrate; and control a dicing driver to cause a portion the first substrate and a portion of the second substrate to be cut into a droplet actuator.
H05K 3/00 - Apparatus or processes for manufacturing printed circuits
H05K 3/02 - Apparatus or processes for manufacturing printed circuits in which the conductive material is applied to the surface of the insulating support and is thereafter removed from such areas of the surface which are not intended for current conducting or shielding
H05K 3/38 - Improvement of the adhesion between the insulating substrate and the metal
26.
REACTION VESSEL MOVING MEMBER FOR MOVING REACTION VESSELS FROM A PROCESSING TRACK TO A ROTATING DEVICE IN A DIAGNOSTIC ANALZYER
A diagnostic analyzer includes a rotating device, a first optical reader, and a second optical reader. The rotating device includes a first darkened compartment, a second darkened compartment, and an optical path along which the first darkened compartment and the second darkened compartment travel. The first optical reader is operable to read the first darkened compartment and the second optical reader is operable to read the second darkened compartment.
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
27.
TECHNOLOGY TO AUTOMATICALLY IDENTIFY THE MOST RELEVANT HEALTH FAILURE RISK FACTORS
A system includes: a processing circuit including a memory device coupled to a processor, the memory device configured to store instructions thereon that, when executed by the processor, cause the processor to: generate synthetic class data using minority class data to obtain balanced class data including the minority class data corresponding to patients with a health failure, the synthetic class data corresponding to the health failure, and majority class data corresponding to patients without the health failure; automatically reduce, using a machine learning classifier, risk factor variables for the health failure to a reduced set of risk factor variables based on the balanced class data; and execute the machine learning classifier using as input a reduced set of risk factor variable data for a patient corresponding to the reduced set of risk factor variables to generate a probability indicator of the health failure for the patient.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
Bodily fluid sampling devices are disclosed herein. An example apparatus is rotatable between a first position and a second position, and includes a wall including a top surface and a slot, a spring, and a carrier coupled to spring. The carrier includes a tab abutting the top surface in the first position. The abutment of the tab and the top surface retains the spring in the first position. The tab is aligned with the slot in the second position.
Provided herein are methods, systems, and kits for determining the concentration or level of an analyte of interest using a competitive and sandwich immunoassay. Also provided herein are acridinium-containing and acridone-containing compounds for use in assays to detect the presence of or determine the concentration or level an analyte of interest in a sample, e.g., a biological sample.
A method for slowing diabetes development in a diabetic or prediabetic individual or reducing a risk of diabetes development in an individual at risk of developing diabetes comprises administering Bifidobacterium animalis subsp. lactis CECT 8145 (BPL1) and a carbohydrate blend to the individual. The carbohydrate blend comprises a source of at least one carbohydrate that provides rapidly available glucose, a source of at least one carbohydrate that provides slowly available glucose, and a source of at least one non-digestible carbohydrate or resistant starch. A nutritional composition comprises protein, fat, the carbohydrate blend, and BPL1.
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
A61K 31/718 - Starch or degraded starch, e.g. amylose, amylopectin
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
31.
HBV DIAGNOSTIC, PROGNOSTIC, AND THERAPEUTIC METHODS AND PRODUCTS
Provided herein are compositions, systems, and methods for assessing and monitory disease stage and phases, predicting likelihood of disease progression, and predicting and monitoring responses to disease therapies (e.g., in HBV infection).
G01N 33/576 - ImmunoassayBiospecific binding assayMaterials therefor for hepatitis
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
32.
DEVICES, SYSTEMS, AND METHODS FOR MAGNETIC-MICROPARTICLE MANIPULATION
The present disclosure provides assay cartridges, sliding magnet arrays, system, and methods that may be used for a range of different assays such as immunoassays, nucleic acid analysis, metabolite analysis, clinical chemistry, and complete blood cell count. The assay cartridges or systems optionally contain a sample analysis region to analyze the samples processed in the device. Assay cartridges comprise a first substrate having a first face comprising a pattern of grooves; a second substrate having a first face, wherein the first substrate is positioned in relation to the second substrate such that the first face of the first substrate faces the first face of the second substrate; and a first region and a second region, wherein the first and second regions are defined by the pattern of grooves and are located between the first and second substrates.
The present disclosure provides a dispensing reagent container that is capable of precise small volume reagent dispensing. The dispensing reagent container comprises a proximal end and a distal end; a first storage region at the proximal end having: a first volume, and a first end at a proximal end having an opening for filling with reagent; a second storage region in fluid communication with the first storage region having a second volume, wherein the second volume is less than the first volume, a dispenser positioned at the distal end of the second storage region; and a plunger having a proximal end and a distal end, wherein: the plunger is positioned coaxially within the reagent container spanning the first storage region and the second storage region, and the distal end of the plunger is capable of being in contact with the dispenser at the distal end of the reagent container.
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes DetailsAccessories therefor
B01F 35/83 - Forming a predetermined ratio of the substances to be mixed by controlling the ratio of two or more flows, e.g. using flow sensing or flow controlling devices
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
B65D 83/685 - Dispensing two or more contents initially separated and subsequently mixed with at least one of the contents stored in a chamber associated with the dispensing head, e.g. for mixing during dispensing
34.
REDUCING AGENT COMPOSITIONS FOR ISOTHERMAL AMPLIFICATION OF NUCLEIC ACIDS
The present disclosure relates to compositions for use in the isothermal amplification of nucleic acids in a sample. In particular, the present disclosure provides compositions that include an activator and reducing agent and methods for amplifying at least one target nucleic acid in a sample using the composition. The present disclosure further provides systems and kits for performing such methods and using such compositions.
Disclosed herein are methods that aid in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or moderate, severe, or moderate to severe traumatic brain injury (TBI), using cTnI. Also disclosed are methods for determining whether to perform a head computerized tomography on a subject by detecting levels of cTnI. Finally, also disclosed are methods of outcome in subjects suffering from a mild TBI.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/533 - Production of labelled immunochemicals with fluorescent label
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
The invention provides methods for determining whether a subject suspected of having a myocardial infarction is experiencing a Type I or Type II myocardial infarction. In particular, systems and methods are provided that employ a probability score based on decision tree based algorithms to process a subject's sex, age, and cardiac troponin concentration(s) and subject's galectin-3 (Gal-3) concentration.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
The present disclosure provides a device that may be used for a range of different assays such as immunoassays, nucleic acid analysis, metabolite analysis, clinical chemistry, and complete blood cell count. The device optionally contains a sample analysis region to analyze the samples processed in the device. The device comprises a top substrate bound to a bottom substrate wherein the top substrate bound to the bottom substrate forms two or more primary zones separated by one or more secondary zones, and wherein the top substrate has an opening in one or more of the primary zones.
Systems, apparatus, articles of manufacture, and methods are disclosed directed to a laboratory diagnostic automation system comprising: interface circuitry; a track to receive and transport receptacles for biological samples; machine-readable instructions; and at least one processor circuit to be programmed by the machine-readable instructions to: determine a throughput state of a medical diagnostic system, determine a processing priority associated with a biological sample to be processed by the laboratory diagnostic automation system as either a first processing priority or a second processing priority; cause dispatch of the biological sample for processing by the laboratory diagnostic automation system based on the processing priority; and cause dispatch of the biological sample for processing by the laboratory diagnostic automation system based on the throughput state.
The present disclosure provides a device that may be used for a range of different assays such as immunoassays, nucleic acid analysis, metabolite analysis, clinical chemistry, and complete blood cell count. The device optionally contains a sample analysis region to analyze the samples processed in the device. The device comprises a top substrate bound to a bottom substrate wherein the top substrate bound to the bottom substrate forms two or more primary zones separated by one or more secondary zones, and wherein the top substrate has an opening in one or more of the primary zones.
The present disclosure provides devices and methods for separation of capture particles into wells of an array of wells and sealing the wells with a hydrophobic liquid. In certain embodiments, the methods of the present disclosure involve detecting presence of a signal from the array of wells, wherein the presence of the signal is indicative of the presence of an analyte immobilized on capture particles. In certain embodiments, the device for separation of capture particles into wells of an array of wells and sealing the wells with a hydrophobic liquid includes protrusions at an opening configured to prevent the hydrophobic liquid from reaching the opening before the hydrophilic liquid is removed.
The present disclosure relate to methods and fluorogenic substrates for analysis of analyte(s) in a sample. The methods include detecting presence of an analyte of interest on capture particles by contacting the capture particles present in nano-chambers with a fluorogenic substrate. The fluorogenic substrate may be of formula (I): (I) wherein: X is selected from a group consisting of H+, K+, Ca2+, tris, triethylammonium, or any other cation; Y is selected from a group consisting of diphosphate, triphosphate, oxymethyl phosphate, or phosphate.
Provided herein are compositions, kits, systems, and methods for detecting antibodies against hepatitis D virus in a sample and for detecting hepatitis D virus infection in a subject.
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
44.
METHODS AND SYSTEMS FOR DIAGNOSING ORTHOPOXVIRUS INFECTION
Provided herein are compositions, methods, and systems for diagnosing orthopoxvirus infection in a subject and/or determining orthopoxvirus vaccination status in a subject.
Example automated diagnostic analyzers and methods for using the same are disclosed herein. An example apparatus described herein includes a first carousel rotatably coupled to a base and having a first axis of rotation. The example apparatus includes a second carousel rotatably coupled to the base and vertically spaced over the first carousel such that at least a portion of the second carousel is disposed over the first carousel. In the example apparatus, the second carousel has a second axis of rotation and a plurality of vessels. The example apparatus also includes a pipetting mechanism offset from the second axis of rotation. The example pipetting mechanism is to access the first carousel and the second carousel.
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
Provided herein are compositions, methods, and systems for diagnosing orthopoxvirus infection in a subject and/or determining orthopoxvirus vaccination status in a subject.
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
G01N 33/576 - ImmunoassayBiospecific binding assayMaterials therefor for hepatitis
47.
METHODS FOR AIDING IN THE DIAGNOSIS AND DETERMINATION OF THE EXTENT OF TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING THE EARLY BIOMARKER UBIQUITIN CARBOXY-TERMINAL HYDROLASE L1
Disclosed herein are methods that aid in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or moderate to severe traumatic brain injury (TBI), using an early biomarker, ubiquitin carboxy-terminal hydrolase L1 (UCH-L1). Also disclosed here are methods that aid in determining whether a human subject that has sustained an injury or may have sustained to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L1. These methods involve detecting levels and changes in levels of UCH-L1 in one or more samples taken from a human subject at time points within 24 hours after the subject has sustained or may have sustained an injury to the head.
A61B 6/50 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body partsApparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific clinical applications
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
48.
Technology to automatically identify the most relevant health failure risk factors
A system includes: one or more processing circuits including one or more memory devices coupled to one or more processors, the one or more memory devices configured to store instructions thereon that, when executed by the one or more processors, cause the one or more processors to: identify minority class data and majority class data in patient-level data, the minority class data corresponding to patients with a health failure, the majority class data corresponding to patients without the health failure; oversample the minority class data to obtain synthetic class data; automatically reduce, using a machine learning classifier, risk factor variables to a reduced set of risk factor variables based on the majority class data, the minority class data, and the synthetic class data; and provide one or more graphical user interfaces for display.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
49.
NUCLEIC ACID AMPLIFICATION REACTION TEST RESULTS VALIDATION
Systems, apparatus, articles of manufacture, and methods are disclosed to validate the results of nucleic acid amplification reaction tests. An example apparatus includes programmable circuitry to at least one of instantiate or execute the machine readable instructions to: calculate differences in amplitudes between consecutive cycles of a plurality of cycles in a fluorescence signal obtained from the test; determine a sum of the differences in amplitudes between consecutive cycles; identify a final amplitude; identify a minimum amplitude of the plurality of cycles; determine a distance as the difference between the final amplitude and the minimum amplitude; determine a ratio of the sum to the distance; and validate the result of the test based on the ratio.
The present disclosure relates to methods for detecting target nucleic acids, e.g., variants of target nucleic acids, in a sample, using two different detection probes for the same target, in two different concentrations. The present disclosure further provides compositions, systems and kits for performing such methods.
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
05 - Pharmaceutical, veterinary and sanitary products
29 - Meat, dairy products, prepared or preserved foods
32 - Beers; non-alcoholic beverages
Goods & Services
Nutritionally fortified dietetic beverages adapted for
medical use. Dairy-based beverages containing fortified nutrients. Non-alcoholic beverages containing fortified nutrients for
use as a healthy snack or meal replacement.
The present disclosure relates to the amplification of nucleic acids in a sample using isothermal application process, e.g., RPA. In particular, the present disclosure provides methods for amplifying at least one target nucleic acid in a sample, where the reagents used in the method include trehalose and polyethylene glycol (PEG). The present disclosure further provides compositions, systems and kits for performing such methods.
A method for maintaining skeletal muscle mobility and/or mass, and/or for recovery of skeletal muscle strength in an individual in need thereof comprises administering β-hydroxy-β-methylbutyrate (HMB) and at least one olive polyphenol to the individual. A nutritional composition for maintaining skeletal muscle mobility and/or mass, and/or for recovery of skeletal muscle strength in an individual comprises HMB, at least one olive polyphenol, and at least one of: at least one source of protein, at least one source of fat, at least one source of carbohydrate.
In one aspect, a computer readable memory medium comprising program instructions for graphically developing a connectivity driver is provided. The computer readable memory medium is a non-transitory medium. The program instructions are executable by a processor to generate a purchase order for a laboratory item, transmit the purchase order to a remote computer in order to communicate the purchase order to a vendor, receive an advance shipping notice generated in response to the purchase order, receive item information stored in an RFID tag of a tagged item received at the delivery location, and check the item information against the advance shipping notice in order to verify that the tagged item is the same as the ordered laboratory item. The purchase order specifies a delivery location.
G06Q 10/08 - Logistics, e.g. warehousing, loading or distributionInventory or stock management
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
G06Q 10/087 - Inventory or stock management, e.g. order filling, procurement or balancing against orders
G06Q 50/22 - Social work or social welfare, e.g. community support activities or counselling services
55.
METHODS FOR AIDING IN THE HYPERACUTE DIAGNOSIS AND DETERMINATION OF TRAUMATIC BRAIN INJURY USING EARLY BIOMARKERS ON AT LEAST TWO SAMPLES FROM THE SAME HUMAN SUBJECT
Disclosed herein are methods that aid in the hyperacute diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild, moderate, severe, or moderate to severe traumatic brain injury (TBI), using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed here are methods that aid in the hyperacute determination of whether a human subject that has sustained an injury or may have sustained to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L1. These methods involve detecting changes of levels of an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a human subject at a time point within about 2 hours, such as about 10, 12, or 20 minutes, after the subject has sustained or may have sustained an injury to the head and a second time point about 3 hours to about 6 hours after the first sample is taken.
A61B 6/50 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body partsApparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific clinical applications
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
56.
METHODS FOR AIDING IN THE DETERMINATION OF WHETHER TO PERFORM IMAGING ON A HUMAN SUBJECT WHO HAS SUSTAINED OR MAY HAVE SUSTAINED AN INJURY TO THE HEAD USING EARLY BIOMARKERS
Disclosed herein are methods that aid in the determination of whether to perform imaging, such as magnetic resonance imaging (MRI) or computerized tomography (CT) scan, on a human subject that has sustained or may have sustained an injury to the head using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. These methods involve detecting levels and changes in levels of UCH-L1 in samples taken from a human subject at time points within 24 hours after the subject has sustained or may have sustained an injury to the head.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 6/50 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body partsApparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific clinical applications
57.
METHODS FOR AIDING IN THE DIAGNOSIS AND EVALUATION OF A SUBJECT WHO HAS SUSTAINED AN ORTHOPEDIC INJURY AND THAT HAS OR MAY HAVE SUSTAINED AN INJURY TO THE HEAD, SUCH AS MILD TRAUMATIC BRAIN INJURY (TBI), USING GLIAL FIBRILLARY ACIDIC PROTEIN (GFAP) AND/OR UBIQUITIN CARBOXY-TERMINAL HYDROLASE L1 (UCH-L1)
Disclosed herein are methods, and kits for use in said methods, that aid in the diagnosis and evaluation of a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed herein are methods, and kits for use in said methods, that aid in determining whether a subject that has sustained an orthopedic injury and sustained or may have sustained an injury to the head would benefit from and thus receive an imaging procedure, such as MRI or head computerized tomography (CT) scan based on the levels of GFAP and/or UCH-L1. These methods involve detecting levels and changes in levels of GFAP and/or UCH-L1 in biological samples taken from a subject at time points within 48 hours after the subject has sustained or may have sustained an injury to the head.
Disclosed herein are methods that aid in the hyperacute diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or moderate, severe, or moderate to severe traumatic brain injury (TBI), using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed here are methods that aid in the hyperacute determination of whether a human subject that has sustained an injury or may have sustained to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L1. These methods involve detecting levels of early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a human subject at a time point within about 2 hours, such as about 10, 12, or 20 minutes, after the subject has sustained or may have sustained an injury to the head.
The present disclosure provides a device that may be used for a range of different assays such as immunoassays, nucleic acid analysis, metabolite analysis, clinical chemistry, and complete blood cell count. The device optionally contains a sample analysis region to analyze the samples processed in the device. The device comprises a top substrate bound to a bottom substrate wherein the top substrate bound to the bottom substrate forms two or more primary zones separated by one or more secondary zones, and wherein the top substrate has an opening in one or more of the primary zones.
Aqueous lipid emulsions for providing enteral nutrition are provided. The aqueous lipid emulsions include at least 33% of lipids, lipid soluble nutrients, or a combination thereof, based upon the total weight of the emulsion, and are essentially free of carbohydrate and protein. The aqueous lipid emulsions are shelf-stable for at least 7 months. The aqueous lipid emulsions are a source of supplemental enteral nutrition for any patient in need thereof, including preterm infants.
A23L 35/00 - Foods or foodstuffs not provided for in groups Preparation or treatment thereof
61.
USE OF ONE OR MORE BIOMARKERS TO DETERMINE TRAUMATIC BRAIN INJURY (TBI) IN A HUMAN SUBJECT HAVING RECEIVED A HEAD COMPUTERIZED TOMOGRAPHY SCAN THAT IS NEGATIVE FOR A TBI
Disclosed herein are methods that aid in the determination of whether a subject has a traumatic brain injury (TBI) by detecting levels of at least one biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a subject, such as a human subject, where the subject has received a head CT scan that is negative for a TBI.
The present disclosure relates to methods for diagnosing and evaluating a subject that has sustained or may have sustained an injury to the head, such as a traumatic brain injury (TBI). In particular, the present disclosure identifies various biomarkers, the detection and/or differential expression of which can be used to assess the presence or absence of a TBI in a subject, and can be used as a basis for diagnosing a subject as having a specific type of TBI (e.g., severe TBI or subclasses of mild TBI). The various TBI biomarkers can be detected individually or in combination and can be used as an important diagnostic, prognostic, and/or TBI risk stratification tool as part of assessing a subject's TBI status.
Disclosed herein are improved methods of processing, measuring, and detecting levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) in blood samples taken from a human subject at time points within about 8 hours (or about 8 hours or less) after obtaining the sample from the subject. UCH-L1 is an early biomarker for traumatic brain injury (TBI), and there is a need for improved methods for assessing UCH-L1 in blood can aid in the diagnosis and evaluation of a human subject who has sustained or may have sustained a head injury.
Bovine milk exosomes are loaded with vitamin D. Nutritional compositions comprise the vitamin D-loaded bovine milk exosomes and at least one of protein, fat and carbohydrate. Methods for manufacturing vitamin D-loaded bovine milk exosomes comprise mixing an aqueous solution of bovine milk exosomes with solubilized vitamin D. A method of preparing a nutritional composition for providing improved bioavailability of vitamin D, or specifically, vitamin D2 and/or vitamin D3 in vivo comprises adding bovine milk exosomes loaded with vitamin D, or specifically, vitamin D2 and/or vitamin D3 to a nutritional composition.
Disclosed herein are systems and methods for determining ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof in a blood sample obtained from a subject. Also disclosed herein are systems and methods for determining CK-MB, β-hCG, thyroid stimulating hormone (TSH), homocysteine, free thyroxine (free T4) or any combinations thereof in a blood sample.
A stabilized fabric composed of a mesh or a woven fabric is disclosed as are methods of their manufacture, the manufacture of medical devices made using a stabilized fibers and stabilized medical devices are all disclosed. Fabrics can be stabilized by several techniques including: using mechanical, chemical and/or energetic fasteners at warp and weft intersections in the weave; by using various weaving techniques and fibers. Meshes can be stabilized when properly dimensioned and arranged junctions and struts of the necessary properties are used. All of these stabilized fabrics can be made of synthetic polymer materials such as ultrahigh molecular weight PE or PP and expanded PTFE.
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
D03D 1/00 - Woven fabrics designed to make specified articles
The disclosure provides methods of analyzing an analyte of interest in a biological sample using fluorescent agents and macroconjugates which comprise a core containing a cross-linked polymer or protein, tags, specific binding members or fragments thereof, and optionally carrier proteins. Also provided are methods of analyzing two or more analytes of interest in a biological sample in a single assay using microparticles and detection conjugates comprising different fluorophore labels, acquiring transmitted light and fluorescent images of the microparticles, and using a customized image analysis process to analyze the acquired images.
In one aspect, a computer readable memory medium comprising program instructions for graphically developing a connectivity driver is provided. The computer readable memory medium is a non-transitory medium. The program instructions are executable by a processor to generate a purchase order for a laboratory item, transmit the purchase order to a remote computer in order to communicate the purchase order to a vendor, receive an advance shipping notice generated in response to the purchase order, receive item information stored in an RFID tag of a tagged item received at the delivery location, and check the item information against the advance shipping notice in order to verify that the tagged item is the same as the ordered laboratory item. The purchase order specifies a delivery location.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
G06Q 10/08 - Logistics, e.g. warehousing, loading or distributionInventory or stock management
G06Q 10/087 - Inventory or stock management, e.g. order filling, procurement or balancing against orders
G06Q 50/22 - Social work or social welfare, e.g. community support activities or counselling services
69.
LATERAL FLOW METHODS, ASSAYS, AND DEVICES FOR DETECTING THE PRESENCE OR MEASURING THE AMOUNT OF UBIQUITIN CARBOXY-TERMINAL HYDROLASE L1 AND/OR GLIAL FIBRILLARY ACIDIC PROTEIN IN A SAMPLE
Disclosed herein are methods and devices for performing at least one lateral flow assay on a biological sample obtained from a subject to determine an amount or presence of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) alone, or an amount or presence of UCH-L1 and an amount or presence of glial fibrillary acidic protein (GFAP).
The present disclosure is directed to bottles that are configured to undergo a controlled collapse in response to pressure being placed on the front and rear walls manually by a user, vacuum forces acting inside the bottle during a tube feeding process, or both. The bottles include a rigid hanging element that is molded into an access channel provided on the base of the bottle, such that the top and sides of the hanging element are fixedly connected with a surface of the container. Due to the presence of the hanging element, the bottle includes hinge lines focus the collapse in the central area of the bottle between the hanging element and the shoulder of the bottle. Accordingly, the present bottles provide both a rigid hanging element and walls that collapse in a controlled manner.
The present disclosure is directed to bottles that are configured to undergo a controlled collapse in response to pressure being placed on the front and rear walls manually by a user, vacuum forces acting inside the bottle during a tube feeding process, or both. The bottles include a rigid hanging element that is molded into an access channel provided on the base of the bottle, such that the top and sides of the hanging element are fixedly connected with a surface of the container. Due to the presence of the hanging element, the bottle includes hinge lines focus the collapse in the central area of the bottle between the hanging element and the shoulder of the bottle. Accordingly, the present bottles provide both a rigid hanging element and walls that collapse in a controlled manner.
Provided herein are methods, systems, and kits for determining late stage liver cancer and monitoring liver cancer status. In particular, methods, systems, and kits are provided that employ the concentration, level, or amount of full-length laminin gamma-2 monomer (LG2m), optionally with the concentration, level, or amount of total LG2m, to determine or identify late stage liver cancer (e.g., hepatocellular carcinoma) in a subject.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
75.
USE OF BIOMARKERS TO DETERMINE WHETHER A SUBJECT HAS SUSTAINED, MAY HAVE SUSTAINED OR IS SUSPECTED OF SUSTAINING A SUBACUTE ACQUIRED BRAIN INJURY (ABI)
Disclosed herein are methods that aid in the determination of whether a subject has or may have sustained an acquired brain injury, such as a traumatic brain injury (TBI), by detecting levels of at least one biomarker, glial fibrillary acidic protein (GFAP), in one or more samples taken from a subject, such as a human subject.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
76.
USE OF BIOMARKERS TO DETERMINE WHETHER A SUBJECT HAS SUSTAINED, MAY HAVE SUSTAINED OR IS SUSPECTED OF SUSTAINING A SUBACUTE ACQUIRED BRAIN INJURY (ABI)
Disclosed herein are methods that aid in the determination of whether a subject has or may have sustained an acquired brain injury, such as a traumatic brain injury (TBI), by detecting levels of at least one biomarker, glial fibrillary acidic protein (GFAP), in one or more samples taken from a subject, such as a human subject.
Rehydration compositions comprise water, at least one electrolyte, and a marine algae polysaccharide, or specifically, fucoidan. A method for rehydrating a subject comprises orally administering a rehydration composition comprising water, at least one electrolyte, and a marine algae polysaccharide, or specifically, fucoidan.
Disclosed herein are methods that aid in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or a moderate, severe, or moderate to severe traumatic brain injury (TBI), by detecting levels of cardiac troponin I (cTnI) and one or more early biomarkers which are not cTnI, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof, in biological samples taken from a human subject at time points within about 24 hours of injury after the subject has sustained or may have sustained the injury to the head.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/533 - Production of labelled immunochemicals with fluorescent label
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
A method of enhancing muscle performance in a subject in need of improved physical performance comprises administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the subject in need thereof. A method of reducing chronic fatigue in a subject recovering or recovered from a viral infection comprises administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the subject.
Example apparatus and methods related to automated diagnostic analyzers having rear accessible track systems are described herein. An example apparatus disclosed herein includes an analyzer to perform a diagnostic test. The analyzer has a first side and a second side opposite the first side. The example apparatus includes a loading bay disposed on the first side of the analyzer to receive a first carrier and a pipetting mechanism coupled to the analyzer adjacent the second side. The example apparatus also includes a first carrier shuttle to transport the first carrier from a first location adjacent the loading bay to a second location adjacent the pipetting mechanism and a track disposed adjacent the second side of the analyzer to transfer a second carrier to a third location adjacent the pipetting mechanism.
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
84.
HIGH THROUGHPUT NUCLEIC ACID TESTING OF BIOLOGICAL SAMPLES
The presently disclosed subject matter relates to methods for rapid, sensitive, and high-throughput nucleic acid testing of biological samples, e.g., blood, serum, or plasma samples from donors, as well as systems capable of performing such high-throughput nucleic acid testing.
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/6848 - Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
Cradles for draining liquid from containers are described herein. An example apparatus includes a housing having a bottom wall, a side wall and an open top. The housing is to receive a container having liquid. The example apparatus includes a probe extending upward from the bottom wall toward the open top and is to drain the liquid from the container when the probe is inserted into the container. The example apparatus also includes a sliding lock slidably disposed within the housing that receives a cap or top of the container when the container is inserted into the housing. The sliding lock includes a key slot. The sliding lock is movable when a cap or top of the container has a matching key that engages the key slot, which enables the sliding lock to move downward to expose the probe and drain the liquid from the container.
Systems and methods for onboard pooling of samples for high-throughput analysis of the samples. Including a sample loading area for receiving a plurality of sample tubes, and a sample transport configured to continually transport individual vessels along a transport path from a sample dispense position to a sample capture and transfer position, with intermediate positions therebetween. At least one pipettor to transfer a first and second samples from the sample loading area to the sample transport and to pool the first sample and the second sample in a vessel on the sample transport to form a pooled sample. A sample transfer mechanism to capture at least a fractionated portion of the pooled sample from the vessel at the sample capture and transfer position and to transfer the at least a fractionated portion of the pooled sample for high-throughput analysis.
G01N 35/02 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor using a plurality of sample containers moved by a conveyor system past one or more treatment or analysis stations
Methods and apparatus to monitor distances traveled by subjects during six-minute walk tests are disclosed. An example system includes a mobile beacon to be carried by a subject during a six-minute walk test, interface circuitry, machine readable instructions, and programmable circuitry to at least one of instantiate or execute the machine readable instructions to determine a distance traveled by the subject during the six-minute walk test based on a strength of signals received from the mobile beacon.
Disclosed herein are methods, kits, and systems for detecting or determining an amount, quantity, concentration and/or level of immunoglobulin G, subclass 4 (LgG4) in a biological sample from a subject. Particularly, the methods, kits and systems are directed to detection of IgG4 using an anti-IgG4 antibody that does not cross-react with other IgG subclasses.
A method for improving bone formation in an individual comprises administering a bovine milk exosome-enriched product and vitamin K2 to the individual. A method for reducing a risk of bone fracture or strengthening bone in an individual comprises administering a bovine milk exosome-enriched product and vitamin K2 to the individual. A method for preventing or delaying onset or development of osteoporosis in an individual comprises administering a bovine milk exosome-enriched product and vitamin K2 to the individual.
A23C 9/142 - Milk preparationsMilk powder or milk powder preparations in which the chemical composition of the milk is modified by non-chemical treatment by dialysis, reverse osmosis or ultrafiltration
A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
Systems, apparatuses and methods may provide technology that automatically converts, by a machine learning model, a Shapley plot into a hazard ratio plot. The technology may also identify a set of preoperative baseline characteristics associated with a procedure on a pooled patient population, determine, by a machine learning model, a set of health failure probabilities for a target patient based on the set of preoperative baseline characteristic and a set of preoperative target characteristics, wherein the set of preoperative target characteristics correspond to the target client, and pair, by the machine learning model, each probability in the set of health failure probabilities with a postoperative dual antiplatelet therapy (DAPT) duration for the target patient.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
05 - Pharmaceutical, veterinary and sanitary products
29 - Meat, dairy products, prepared or preserved foods
Goods & Services
(1) Dietary and nutritional supplements for general health and wellbeing; food for babies and infants; food preparations for babies and infants; infant formula; milk for babies; milk formula for babies; milk powder for babies; milk powder for nutritional purposes for babies; milk substitutes for babies; nutritional supplements for infant and child health and well-being; powdered milk for babies and infants; vitamin and mineral food supplements; vitamin and mineral supplements for use in infant formulas
(2) Coconut milk; lactose-free milk; milk and milk products; milk powder; milk-based beverages; non-dairy milk; plant-based milk substitutes; powdered milk
92.
DUAL ANTIPLATELET THERAPY AND TIME BASED RISK PREDICTION
Systems, apparatuses and methods may provide technology that automatically converts, by a machine learning model, a Shapley plot into a hazard ratio plot. The technology may also identify a set of preoperative baseline characteristics associated with a procedure on a pooled patient population, determine, by a machine learning model, a set of health failure probabilities for a target patient based on the set of preoperative baseline characteristic and a set of preoperative target characteristics, wherein the set of preoperative target characteristics correspond to the target client, and pair, by the machine learning model, each probability in the set of health failure probabilities with a postoperative dual antiplatelet therapy (DAPT) duration for the target patient.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
93.
METHODS OF IDENTIFYING MACROTROPONIN IN BIOLOGICAL SAMPLES
42 - Scientific, technological and industrial services, research and design
Goods & Services
Providing online non-downloadable software in the field of nutrition for measuring and mixing infant and toddler formulas; providing temporary use of online non-downloadable computer software in the field of pediatric nutrition calculation; providing online non-downloadable software for healthcare professionals to create, organize, analyze, compare, manage, maintain, share, and store data in the field of pediatric nutrition.
95.
METHODS AND APPARATUS TO REDUCE ANXIETY WITH MIXED REALITY
Methods and apparatus to reduce anxiety using mixed reality are disclosed herein. An example method of reducing anxiety in a person during a blood collection process includes providing a mixed reality headset to a person prior to collecting blood from the person. The method includes initiating a mixed reality program on the mixed reality headset. The mixed reality program causes a display device to display a mixed reality environment with one or more virtual objects on glasses of the headset, determines a gaze direction of the eyes of the person, and causes a change in one or more of the virtual objects in the mixed reality environment based on the gaze direction. The method further includes collecting blood from the person while the person is exposed to the mixed reality program.
G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
A61B 5/16 - Devices for psychotechnicsTesting reaction times
A61M 21/00 - Other devices or methods to cause a change in the state of consciousnessDevices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
96.
METHODS OF DIAGNOSING OR AIDING IN DIAGNOSIS OF BRAIN INJURY CAUSED BY ACOUSTIC ENERGY, ELECTROMAGNETIC ENERGY, AN OVER PRESSURIZATION WAVE, AND/OR BLAST WIND
Disclosed herein are methods of aiding in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head, such as mild, moderate, severe, or moderate to severe traumatic brain injury (TBI) by detecting levels of a biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a subject (e.g., a human subject) that has or may have sustained an injury or suspected injury to the head that is caused or believed to have been caused by acoustic energy, electromagnetic energy (e.g., from a sonic weapon, a directed energy weapon or a combination thereof), an over pressurization wave, blast wind, or any combination thereof.
Provided herein are compositions, systems, and methods for assessing and monitoring disease stage and phases, predicting likelihood of disease progression, and predicting and monitoring responses to hepatitis B virus infection.
Disclosed are methods for detecting a target nucleic acid in a sample. The methods include contacting the sample, in the presence of a polymerase and an endonuclease, with a first oligonucleotide that includes, in the 5′ to 3′ direction, a signal DNA generation sequence, an endonuclease recognition site, and a complementary sequence that has at least one abasic moiety and wherein the complementary sequence has a first complementary sequence that is complementary to at least a portion of the signal DNA generation sequence and a second complementary sequence that is complementary to the 3′ end of the target nucleic acid. Also disclosed are methods that include a second oligonucleotide including, in the 5′ to 3′ direction, a second signal DNA generation sequence, an endonuclease recognition site, and a sequence that is homologous to the first signal DNA generation sequence of the first oligonucleotide and that optionally has at least one abasic site. Also disclosed chemically modified oligonucleotides, as well as compositions and kits that include the chemically modified oligonucleotides for detecting a target nucleic acid.
Disclosed herein are methods for aiding in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head, such as to determine whether the subject is suffering from a mild or a supermild traumatic brain injury.
A nutritional composition for use in enhancing one or more features or functions of the blood-brain barrier, including promoting healing or improved function of the blood-brain barrier. In certain embodiments, a method comprises administering to an individual in need thereof a nutritional composition comprises at least one human milk oligosaccharide as described herein to treat or prevent one or more blood-brain barrier related conditions.
A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
